Baillie Gifford (688506.SH): plans to raise no more than 3.9 billion yuan through a private placement.

GLONGHUI reported on March 9 that Baili Tianheng (688506.SH) announced a plan to issue A shares to specific targets for the year 2025. The total amount of funds raised from this issuance will not exceed 3.9 billion yuan (including the principal), and after deducting issuance expenses, it will be used for Innovative Drugs research and development projects.

Gelonghui FinanceMar 9 15:37

Sichuan Biokin Pharmaceutical Enrolls First Patient for Lung Cancer Trial; Shares Down 4%

MT NewswiresMar 3 12:21

Bailitihanheng (688506.SH): The innovative biological drug injection BL-B01D1 has completed the enrollment of the first subject in the phase III clinical trial.

Baile Tianheng (688506.SH) announced that the company's independently developed innovative biological drug, injectable BL-B01...

Zhitong FinanceMar 2 17:17

Express News | Baili Tianheng: The first subject has been enrolled in the Phase III clinical trial of BL-B01D1 combined with Osimertinib for first-line treatment of locally advanced or metastatic non-small cell lung cancer with EGFR mutations.

BreakingsMar 2 15:41

Bailitianheng (688506): In 2025, intensive catalysts will be welcomed, and the Global potential of BL-B01D1 is gradually emerging.

The company announced the 2024 performance report on February 27: achieving a total revenue of approximately 5.823 billion yuan (+936.3% year-on-year), with net income attributable to the parent company/adjusted net income of 3.658/3.604 billion yuan.

HTSCFeb 28 00:00

Baili Tianheng: Sichuan Baili Tianheng Pharmaceutical Co., Ltd. 2024 Annual Results Express Announcement

SZSIFeb 28 00:00 · Announcements